Causes of Hyperkalemia
Hyperkalemia results from three primary mechanisms: impaired renal potassium excretion (most common), transcellular shifts of potassium from intracellular to extracellular space, and excessive potassium intake—with the vast majority of clinically significant cases occurring when impaired excretion is combined with one or both of the other mechanisms 1, 2.
Primary Mechanisms and Clinical Causes
Impaired Renal Excretion (Most Common)
The kidney is the primary route of potassium elimination, and hyperkalemia occurs when renal excretion is limited by:
- Reduced glomerular filtration rate (chronic kidney disease, acute kidney injury)
- Decreased tubular flow
- Reduced distal sodium delivery
- Impaired aldosterone-sensitive ion transporter expression in the distal nephron 2
Medication-Induced Hyperkalemia
RAASi therapies are the leading medication cause, particularly in patients with underlying chronic conditions 3:
- Angiotensin-converting enzyme inhibitors (ACEi)
- Angiotensin receptor blockers (ARBs)
- Angiotensin receptor-neprilysin inhibitors
- Mineralocorticoid receptor antagonists (MRAs)—both steroidal and non-steroidal
- Potassium-sparing diuretics 4, 2
The combination of these medications dramatically increases risk, as demonstrated by the case of concomitant enalapril and spironolactone causing severe hyperkalemia (potassium 8.9 mEq/L) 5.
High-Risk Patient Populations
The major risk factors cluster around specific chronic conditions 2:
- Chronic kidney disease (3.8-fold increased risk of acute hospitalization, 4.9-fold increased mortality) 3
- Heart failure (2.8-fold increased hospitalization, 3.4-fold increased mortality) 3
- Diabetes mellitus (impairs potassium regulation and often coexists with CKD)
- Adrenal disease (hypoaldosteronism) 1, 2
Transcellular Shifts
Potassium movement from intracellular to extracellular space occurs with:
- Hyperglycemia 6
- Metabolic acidosis
- Tissue breakdown (rhabdomyolysis, tumor lysis)
- Medications (beta-blockers, digoxin toxicity)
Often-Overlooked Causes
Pseudohyperkalemia must be excluded before treatment 1:
- Hemolysis during blood draw
- Repeated fist clenching during phlebotomy
- Prolonged tourniquet time
- Slow specimen processing
- Thrombocytosis or leukocytosis (platelet/white cell potassium release during clotting)
Hypoaldosteronism can cause hyperkalemia even with normal or mildly impaired kidney function 1, making it a critical diagnosis in patients without obvious renal disease.
Clinical Context and Pitfalls
The combination of multiple risk factors exponentially increases hyperkalemia risk. A patient with CKD stage 3, diabetes, and heart failure on ACEi plus spironolactone represents the highest-risk scenario 3, 4.
Plasma potassium concentrations are 0.1-0.4 mEq/L lower than serum levels due to platelet potassium release during coagulation 7. This technical detail matters when interpreting borderline values.
Circadian rhythm affects potassium homeostasis, so timing of sample collection influences results 7.
Critical Monitoring Points
Following RAASi initiation or dose escalation, potassium should be measured within 7-10 days 7. More frequent monitoring is warranted in patients with CKD, diabetes, heart failure, or prior hyperkalemia history 7.
Every 0.1 mEq/L rise in serum potassium ≥5.0 mEq/L significantly increases all-cause mortality 3, emphasizing that even mild elevations carry prognostic significance beyond arbitrary thresholds.